Abametapir

  • TRADE NAME: Xeglyze (Dr Reddy's Laboratories)
  • INDICATIONS: Topical treatment of head lice infestation
  • CLASS: Metalloproteinase inhibitor, Pediculocide
  • HALF-LIFE: 71 ± 40 hours (data for a metabolite)

FDA APPROVAL DATE: 07/24/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

CYP3A4, CYP2B6, CYP1A2 substrates

PREGNANCY CATEGORY: N/A
No available data

Abametapir is formulated with benzyl alcohol. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants. Use of the formulated product is not recommended in pediatric patients under 6 months of age because of the potential for increased systemic absorption.

Our database has 8 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
GASTROINTESTINAL/HEPATIC.
OCULAR.


Page last updated 03/31/2021

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top